Treatment of pediatric refractory Crohn's disease with thalidomide

World Journal of Gastroenterology

Volumn 17, Issue 10, 2011, Pages 1286-1291

  Zheng, Cui Fang ^a   Xu, Jia Hua ^a   Huang, Ying ^a   Leung, Ying Kit ^a  

^a CHILDREN S HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Children; Inflammatory bowel disease; Thalidomide; Tumor necrosis factor

Indexed keywords

THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CROHN DISEASE; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; ONSET AGE; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79955930523     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i10.1286     Document Type: Article

References (34)

1. Maeda K, Okada M, Yao T, Sakurai T, Iida M, Fuchigami T, Yoshinaga K, Imamura K, Okada Y, Sakamoto K. Intestinal and extraintestinal complications of Crohn's disease: predictors and cumulative probability of complications. J Gastroenterol 1994; 29: 577-582
2. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006; 12: 4819-4831
3. Gabalec L, Bures J, Sedová M, Valenta Z. [Quality of life of Crohn's disease patients]. Cas Lek Cesk 2009; 148: 201-205
4. Cohen RD. The quality of life in patients with Crohn's disease. Aliment Pharmacol Ther 2002; 16: 1603-1609
5. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703
6. Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999; 58 Suppl 1: I107-I113
7. Dredge K, Marriott JB, Dalgleish AG. Immunological effects of thalidomide and its chemical and functional analogs. Crit Rev Immunol 2002; 22: 425-437
8. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91: 4082-4085
9. Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, Stirling D, Dalgleish AG. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002; 87: 1166-1172
10. Kaplan G, Thomas S, Fierer DS, Mulligan K, Haslett PA, Fessel WJ, Smith LG, Kook KA, Stirling D, Schambelan M. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses 2000; 16: 1345-1355
11. Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C, Bréant C, Mathivet T, Larrivée B, Thomas JL, Arthur HM, Westermann CJ, Disch F, Mager JJ, Snijder RJ, Eichmann A, Mummery CL. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010; 16: 420-428
12. Coelho A, Souto MI, Cardoso CR, Salgado DR, Schmal TR, Waddington Cruz M, de Souza Papi JA. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. Lupus 2005; 14: 434-439
13. van de Donk NW, Kröger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MH, Nagler A, Verdonck LF, Lokhorst HM. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 2006; 107: 3415-3416
14. Direskeneli H, Ergun T, Yavuz S, Hamuryudan V, Eksioglu- Demiralp E. Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease. Clin Rheumatol 2008; 27: 373-375
15. Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, Griffiths AM, Katz AJ, Grand RJ, Boyle JT. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991; 12: 439-447
16. McDermott MF. TNF and TNFR biology in health and disease. Cell Mol Biol (Noisy-le-grand) 2001; 47: 619-635
17. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficientmice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996; 184: 1397-1411
18. Marino MW, Dunn A, Grail D, Inglese M, Noguchi Y, Richards E, Jungbluth A, Wada H, Moore M, Williamson B, Basu S, Old LJ. Characterization of tumornecrosis factor-deficient mice. Proc Natl Acad Sci USA 1997; 94: 8093-8098
19. Wada H, Saito K, Kanda T, Kobayashi I, Fujii H, Fujigaki S, Maekawa N, Takatsu H, Fujiwara H, Sekikawa K, Seishima M. Tumor necrosis factor-alpha (TNF-alpha) plays a protective role in acute viralmyocarditis in mice: A study using mice lacking TNF-alpha. Circulation 2001; 103: 743-749
20. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997; 40: 443-448
21. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-135
22. Oussalah A, Danese S, Peyrin-Biroulet L. Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. Curr Drug Targets 2010; 11: 156-175
23. Bell S, Kamm MA. Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease. Lancet 2000; 355: 858-860
24. Nakamura K, Honda K, Mizutani T, Akiho H, Harada N. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol 2006; 12: 4628-4635
25. Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, Sarno EN. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993; 168: 408-414
26. Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002; 50: 196-200
27. Prakash O, Medhi B, Saikia UN, Pandhi P. Effect of different doses of thalidomide in experimentally induced inflammatory bowel disease in rats. Basic Clin Pharmacol Toxicol 2008; 103: 9-16
28. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999; 117: 1271-1277
29. Casella G, De Marco E, Monti C, Baldini V. The therapeutic role of thalidomide in inflammatory bowel disease. Minerva Gastroenterol Dietol 2006; 52: 293-301
30. Lazzerini M, Martelossi S, Marchetti F, Scabar A, Bradaschia F, Ronfani L, Ventura A. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment Pharmacol Ther 2007; 25: 419-427
31. De Sanctis JB, Mijares M, Suárez A, Compagnone R, Garmendia J, Moreno D, Salazar-Bookaman M. Pharmacological properties of thalidomide and its analogues. Recent Pat Inflamm Allergy Drug Discov 2010; 4: 144-148
32. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314-322
33. Corral LG, Muller GW, Moreira AL, Chen Y, Wu M, Stirling D, Kaplan G. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996; 2: 506-515
34. Oliver SJ, Freeman SL, Corral LG, Ocampo CJ, Kaplan G. Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis. Clin Exp Immunol 1999; 118: 315-321.